|Download document||Guideline on good pharmacovigilance practices (GVP) 3 - Module V – Risk management systems (Rev 2)|
|Reference number||EMA/838713/2011 Rev. 2|
|Status||draft: consultation open|
|Consultation start date||29/02/2016|
|Consultation end date||31/05/2016|
|Email address for email@example.com|
Good pharmacovigilance practices (GVP) module V, released in 2012, advises developers of medicines, marketing authorisation holders and regulators on the design of effective risk management systems and plans. This first major revision clarifies the activities a risk management plan should focus on during the life cycle of a product. This will help to ensure that a risk-proportionate planning of activities directs resources to areas where the need for additional information and risk minimisation is greatest.